Compare Crocs, Inc. (CROX) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crocs, Inc. vs Cytokinetics Inc — how do they compare? Crocs, Inc. trades at $130.4 (market cap $6.31B), while Cytokinetics Inc trades at $76.53 (market cap $10.63B). The key difference: Cytokinetics Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| CROX | CYTK | |
|---|---|---|
Market Cap | $6.31B | $10.63B |
Sector | Consumer Staples | Technology |
52-Week High | $141.19 | $87.26 |
52-Week Low | $73.39 | $34.31 |
Enterprise Value | $7.83B | $10.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Crocs (CROX) trades at $130.39, down 5.65% over 24 hours, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability metrics, including a 57.47% gross margin and 42.3% ROE, but faces headwinds from a net loss in 2025 and negative sentiment around tax practices. Recent news highlights a raised full-year outlook post-Q2 results, though near-term guidance disappointed investors.
The outlook is mixed: valuation ratios like P/E of 11.69 appear attractive, and analyst consensus leans bullish with a $140.43 price target. However, risks include tax scrutiny, HEYDUDE brand weakness, and volatile cash flows. Upside depends on execution of DTC and international growth strategies amid competitive pressures.
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
